Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + GCVP in Untreated Follicular Lymphoma
NCT06918015Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2025
- Primary completion
- May 2028
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in follicular lymphoma (FL), sponsored by Zhejiang Cancer Hospital. Planned start May 2025; status: not yet recruiting.
02
Drugs
zanubrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06918015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06918015.